Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen’s proprietary RenLite platform and associated intellectual property. This collaboration aims to discover, research, develop, manufacture, and commercialize fully human antibody therapeutics with a common light chain, as well as other biological therapeutics, for an unlimited number of drug targets and indications. Financial terms of the agreement were not disclosed.
About the RenLite Platform
RenLite is an integral part of Biocytogen’s fully human antibody RenMice family. This innovative platform enables the generation of fully human antibody candidates that exhibit high specificity, affinity, diversity, and good druggability. A distinctive feature of RenLite mice is their ability to produce antibodies with a common light chain, which is crucial for the subsequent assembly of bispecific and multi-specific antibodies. This approach results in a low mismatch rate and a high success rate, making it an attractive option for the development of complex therapeutics.
Advantages for Therapeutics Development
The bispecific and multi-specific antibodies developed through the RenLite platform maintain a traditional antibody structure. This characteristic is beneficial as it ensures ideal physiochemical properties, which are advantageous for downstream chemical, manufacturing, and control (CMC) development. The agreement with Janssen Biotech Inc. underscores the potential of the RenLite platform to contribute significantly to the advancement of antibody therapeutics globally.-Fineline Info & Tech
